Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients
Eli Lilly's Investigational Cancer Drug Cuts Risk Of Death By 38% In Breast Cancer Patients
Imlunestrant in combination with Eli Lilly's Verzenio (abemaciclib) reduced the risk of progression or death by 43% versus imlunestrant alone, in all patients.On Wednesday, Eli Lilly And Co (NYSE:LLY) announced results from the Phase 3 EMBER-3 study of imlunestrant for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative advanced breast cancer, whose disease progressed on a prior aromatase inhibitor, with or without a CDK4/6 inhibitor.
在周三，礼来（纽交所：LLY）公布了针对雌激素受体阳性（ER+）、人类表皮生长因子受体2阴性、在先前的芳香化酶抑制剂治疗后疾病进展的晚期乳腺癌的第3期EMBER-3研究的结果，该研究探索了imlunestrant的疗效。
Imlunestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) as monotherapy in patients with an ESR1 mutation versus standard of care endocrine therapy (SOC ET), reducing the risk of disease progression or death by 38%.
与标准的内分泌治疗（SOC ET）相比，imlunestrant在具有ESR1突变的患者中作为单药治疗显示出统计学显著和临床意义的无进展生存期（PFS）改善，将疾病进展或死亡的风险降低了38%。
Also Read: What's Going On With Eli Lilly Stock On Tuesday?
另请阅读：礼来股票周二发生了什么？
Imlunestrant in combination with Eli Lilly's Verzenio (abemaciclib) reduced the risk of progression or death by 43% versus imlunestrant alone, in all patients.
与礼来的Verzenio（abemaciclib）联合使用时，imlunestrant在所有患者中将疾病进展或死亡的风险降低了43%，相比之下，单独使用imlunestrant的效果较差。
Imlunestrant significantly improved progression-free survival versus standard-of-care endocrine therapy in patients with an ESR1 mutation.
在具有ESR1突变的患者中，imlunestrant显著改善了无进展生存期，对比标准内分泌治疗。
In patients with an ESR1 mutation, the median progression-free survival was 5.5 months with imlunestrant versus 3.8 months with standard-of-care endocrine therapy.
在具有ESR1突变的患者中，使用imlunestrant的中位无进展生存期为5.5个月，而标准内分泌治疗为3.8个月。
The overall response rate (ORR) with imlunestrant was 14% compared to 8% with SOC ET in patients with an ESR1 mutation.
在具有ESR1突变的患者中，使用imlunestrant的总体反应率（ORR）为14%，而标准内分泌治疗（SOC ET）为8%。
In all patients, the median PFS was 5.6 months with imlunestrant versus 5.5 months with standard-of-care endocrine therapy and did not reach statistical significance.
在所有患者中，使用imlunestrant的中位PFS为5.6个月，而标准内分泌治疗为5.5个月，未达到统计学显著性。
Imlunestrant-abemaciclib significantly improved PFS compared to imlunestrant in all patients, regardless of ESR1 mutation status, with median PFS of 9.4 months for imlunestrant-abemaciclib versus 5.5 months for imlunestrant alone.
Imlunestrant-abemaciclib与imlunestrant相比，在所有患者中显著改善了无进展生存期（PFS），无论ESR1突变状态如何，Imlunestrant-abemaciclib的中位PFS为9.4个月，而imlunestrant单独使用的中位PFS为5.5个月。
In all patients, the ORR with imlunestrant-abemaciclib was 27% compared to 12% with imlunestrant alone.
在所有患者中，Imlunestrant-abemaciclib的客观缓解率（ORR）为27%，而单独使用imlunestrant的客观缓解率为12%。
Overall survival (OS) results for EMBER-3 were immature at the time of analysis. The trial will continue to assess OS as a secondary endpoint.
EMBER-3的总体生存率（OS）结果在分析时尚不成熟。该试验将继续评估生存率作为次要终点。
Imlunestrant is also being investigated in the adjuvant setting in people with ER+, HER2- early breast cancer with an increased risk of recurrence. This Phase 3 trial EMBER-4 is expected to enroll 6,000 patients.
Imlunestrant在ER+、HER2-早期乳腺癌的辅助治疗中也正在研究，这些患者具有较高的复发风险。该3期试验EMBER-4预计将招募6000名患者。
Price Action: LLY stock is down 1.20% at $790.01 at the last check on Wednesday.
价格动态：截至周三最后检查时，LLY股票下跌1.20%，报790.01美元。
- Why Is Fertility Services Provider NewGenIvf Stock Rocketing On Wednesday?
- 为什么生育服务提供商NewGenIvf的股票在星期三大涨？
Photo via Shutterstock
照片来源于Shutterstock
